GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2017 Financial Results

Global Blood Therapeutics (GBT) (NASDAQ:GBT) today reported recent business progress and financial results for the fourth quarter and year ended December 31, 2017.

As quoted in the press release:

“We continue to build positive momentum toward bringing voxelotor, the first and only sickle cell disease (SCD) treatment to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration, to the SCD community,” said Ted W. Love, M.D., president and chief executive officer of GBT. “We expect to continue this momentum in 2018, as we expect to announce top-line clinical data from our ongoing voxelotor clinical programs – HOPE Study Part A and HOPE-KIDS 1 Study. We are also working diligently to diversify our pipeline, both through our internal research as well as through business development efforts, by exploring innovative opportunities that have the potential to make a significant difference in the lives of underserved patient communities.”

Click here to read the full press release.